Robert Venning Bryant1,2, Christopher G Schultz3, Soong Ooi4, Charlotte Goess4, Samuel Paul Costello1,2, Andrew D Vincent5, Scott Schoeman1, Amanda Lim1, Francis Dylan Bartholomeusz3, Simon P L Travis6, Jane Mary Andrews2,4. 1. IBD Service, Department of Gastroenterology and Hepatology, The Queen Elizabeth Hospital, Woodville South, South Australia. 2. School of Medicine, Faculty of Health Sciences, University of Adelaide, Adelaide, South Australia. 3. Department of Nuclear Medicine, PET and Bone Densitometry, Royal Adelaide Hospital, Adelaide, South Australia. 4. IBD Service, Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, South Australia. 5. Freemasons Foundation Centre for Men's Health, School of Medicine, University of Adelaide, Adelaide, South Australia. 6. Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford, Oxfordshire, UK.
Abstract
BACKGROUND: Visceral adipose tissue (VAT) has been proposed to play a pathogenic role in Crohn's disease (CD); however, prospective clinical data are lacking. The aim was to evaluate whether VAT, beyond body mass index (BMI), is associated with CD behavior, disease activity, quality of life (QoL), or outcomes. METHODS: Body composition data and clinical, anthropometric, disease activity (fecal calprotectin [FC]), and QoL scores were gathered prospectively on adults with CD at 0, 12, and 24 months. BMI and, VAT metrics (visceral adipose tissue volume [cm3]/height [m2] index and VAT:subcutaneous adipose tissue [SAT] ratio) were calculated. Inflammatory bowel disease-related surgery and hospitalization were recorded over extended follow-up (median, 51 months). Multivariable linear mixed effects and logistic regression analyses were performed. RESULTS: Ninety-seven participants were assessed at baseline (55% male; median age, 31 years), 84 at 12 months, and 72 at 24 months. VAT:SAT was positively associated with stricturing disease behavior (log odds ratio [OR], 1.7; 95% confidence interval [CI], 0.32 to 3; P = 0.01) and elevated FC in patients with ileocolonic disease (β, 1.3; 95% CI, 0.32 to 2.3; P = 0.01). VAT:SAT was associated with lower QoL, particularly in those with ileal disease (β, -12; 95% CI, -19 to -4.5; P = 0.05). However, no prospective associations were observed between serial VAT measurements and time to surgery or hospitalization. No correlations were found between BMI and disease behavior, activity, or QoL. CONCLUSIONS: VAT:SAT, rather than BMI, is associated with stricturing CD behavior, elevated FC, and reduced QoL in a disease distribution-dependent manner. Further studies are required to substantiate the role of VAT as a useful biomarker in CD.
BACKGROUND: Visceral adipose tissue (VAT) has been proposed to play a pathogenic role in Crohn's disease (CD); however, prospective clinical data are lacking. The aim was to evaluate whether VAT, beyond body mass index (BMI), is associated with CD behavior, disease activity, quality of life (QoL), or outcomes. METHODS: Body composition data and clinical, anthropometric, disease activity (fecal calprotectin [FC]), and QoL scores were gathered prospectively on adults with CD at 0, 12, and 24 months. BMI and, VAT metrics (visceral adipose tissue volume [cm3]/height [m2] index and VAT:subcutaneous adipose tissue [SAT] ratio) were calculated. Inflammatory bowel disease-related surgery and hospitalization were recorded over extended follow-up (median, 51 months). Multivariable linear mixed effects and logistic regression analyses were performed. RESULTS: Ninety-seven participants were assessed at baseline (55% male; median age, 31 years), 84 at 12 months, and 72 at 24 months. VAT:SAT was positively associated with stricturing disease behavior (log odds ratio [OR], 1.7; 95% confidence interval [CI], 0.32 to 3; P = 0.01) and elevated FC in patients with ileocolonic disease (β, 1.3; 95% CI, 0.32 to 2.3; P = 0.01). VAT:SAT was associated with lower QoL, particularly in those with ileal disease (β, -12; 95% CI, -19 to -4.5; P = 0.05). However, no prospective associations were observed between serial VAT measurements and time to surgery or hospitalization. No correlations were found between BMI and disease behavior, activity, or QoL. CONCLUSIONS: VAT:SAT, rather than BMI, is associated with stricturing CD behavior, elevated FC, and reduced QoL in a disease distribution-dependent manner. Further studies are required to substantiate the role of VAT as a useful biomarker in CD.
Authors: Jessica A Fitzpatrick; Sarah L Melton; Chu Kion Yao; Peter R Gibson; Emma P Halmos Journal: Nat Rev Gastroenterol Hepatol Date: 2022-05-16 Impact factor: 73.082
Authors: Nik Sheng Ding; Daniel Tassone; Ibrahim Al Bakir; Kyle Wu; Alexander J Thompson; William R Connell; George Malietzis; Phillip Lung; Siddharth Singh; Chang-Ho Ryan Choi; Simon Gabe; John T Jenkins; Ailsa Hart Journal: J Crohns Colitis Date: 2022-09-08 Impact factor: 10.020
Authors: Jan Bilski; Agnieszka Mazur-Bialy; Dagmara Wojcik; Marcin Surmiak; Marcin Magierowski; Zbigniew Sliwowski; Robert Pajdo; Slawomir Kwiecien; Aleksandra Danielak; Agata Ptak-Belowska; Thomas Brzozowski Journal: Biomolecules Date: 2019-11-26
Authors: Giuseppe Losurdo; Rosa Federica La Fortezza; Andrea Iannone; Antonella Contaldo; Michele Barone; Enzo Ierardi; Alfredo Di Leo; Mariabeatrice Principi Journal: World J Gastroenterol Date: 2020-12-21 Impact factor: 5.742
Authors: Eva Karaskova; Maria Velganova-Veghova; Milos Geryk; Hana Foltenova; Veronika Kucerova; David Karasek Journal: Int J Mol Sci Date: 2021-04-19 Impact factor: 5.923